Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy
暂无分享,去创建一个
F. Reyal | J. Pierga | E. Laas | M. Laé | A. Hamy | F. Lerebours | L. Darrigues | M. Osdoit | G. Lam | M. Faron | J. Féron | D. de Croze | Sonia Rozette | Clémence Evrevin | Lucie Laot | L. Topciu
[1] L. Esserman,et al. Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis , 2020 .
[2] A. Vincent-Salomon,et al. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy , 2019, Clinical Cancer Research.
[3] P. Fasching,et al. Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.
[4] A. Vincent-Salomon,et al. Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma , 2018, Breast Cancer Research and Treatment.
[5] F. Rojo,et al. Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. , 2017, The oncologist.
[6] T. Nielsen,et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. , 2017, Seminars in cancer biology.
[7] A. Vincent-Salomon,et al. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] L. Emens. Breast Cancer Immunotherapy: Facts and Hopes , 2017, Clinical Cancer Research.
[9] Jeffrey I. Campbell,et al. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) , 2017, Breast Cancer Research and Treatment.
[10] Sung-Bae Kim,et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy , 2017, The New England journal of medicine.
[11] Donald A. Berry,et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. , 2017 .
[12] Mei Liu,et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Janice S. Sung,et al. A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling , 2016, Clinical Cancer Research.
[14] G. Hortobagyi,et al. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. , 2016, JAMA oncology.
[15] Mitchell D Schnall,et al. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. , 2016, Radiology.
[16] S. Mallal,et al. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors , 2015, Clinical Cancer Research.
[17] Christos Hatzis,et al. Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy , 2015, Modern Pathology.
[18] L. Esserman,et al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] S. Jung,et al. Value of 18F-FDG PET/CT for Early Prediction of Pathologic Response (by Residual Cancer Burden Criteria) of Locally Advanced Breast Cancer to Neoadjuvant Chemotherapy , 2014, Clinical nuclear medicine.
[20] Gideon Blumenthal,et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.
[21] Elizabeth L. Cureton,et al. Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657) , 2014, Annals of Surgical Oncology.
[22] Yan Peng,et al. Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer. , 2014, Human pathology.
[23] L. Pusztai,et al. Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes , 2013 .
[24] A. Taghian,et al. Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application. , 2013, Archives of pathology & laboratory medicine.
[25] J. García-Saenz,et al. Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] P. Fasching,et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Stef van Buuren,et al. MICE: Multivariate Imputation by Chained Equations in R , 2011 .
[28] Peter Regitnig,et al. Genomic index of sensitivity to endocrine therapy for breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] P. LoRusso,et al. Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells , 2010, Clinical Cancer Research.
[30] G. Hortobagyi,et al. Staging of breast cancer in the neoadjuvant setting. , 2008, Cancer research.
[31] Janice N Cormier,et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Christos Hatzis,et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[34] Roman Rouzier,et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.
[35] C K Osborne,et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] M. Dowsett,et al. Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .